Verastem, Inc.
VSTM · Nasdaq · United States
Share price · VSTM
Loading chart…
Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento
Unusual price moves
Days when VSTM's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked
- 6 Nov 2026-10.3%
- Day beforeRegulation FD disclosure
- 22 Oct 2026+9.2%
- 15 Oct 2026+19.7%
- 13 Oct 2026-9.7%
Nothing announced by VSTM that day or the session before.
- 7 Oct 2026+6.6%
Nothing announced by VSTM that day or the session before.
- 7 Aug 2026+14.0%
- 1 Jul 2026+7.3%
Nothing announced by VSTM that day or the session before.
- 25 Jun 2026-10.4%
Nothing announced by VSTM that day or the session before.
- 24 Jun 2026-8.6%
- 8 May 2026-13.6%
Share of unusual movement by asset
For each asset, the share of VSTM's own-move activity since 2 Jul 2024 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.
Assets
(2 total)
| Target & Modality | |||
|---|---|---|---|
| Approved | MEK1/2 and RAF (CRAF, BRAF) · FAKSmall molecule | Ovarian Cancer | |
| Phase 3 | KRAS G12DSmall molecule | Non-Small Cell Lung CancerPancreatic Ductal Adenocarcinoma |
Upcoming events
(13 total)
Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
2027 (7)
April 2027 (1)
June 2027 (4)
July 2027 (1)
August 2027 (1)
What to watch
2028 (5)
July 2028 (1)
August 2028 (1)
October 2028 (1)
What to watch
November 2028 (1)
December 2028 (1)
What to watch
Regulatory and conference events
(1)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Recent
Financial reports
Quarterly & interim (17)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q3 | $24M | $69M | $173M | $75M-$34M operating cash flow | report ↗ |
View 16 more
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q2 | — | $41M | $137M+ $0.1M short-term inv. | $35M-$44M operating cash flow | report ↗ |
| 2026-Q1 | — | $38M | $166M+ $16M short-term inv. | $37M-$52M operating cash flow | report ↗ |
| 2025-Q4 | $18M | $32M | $205M | $33M | report ↗ |
| 2025-Q3 | — | $29M | $138M | $99M-$36M operating cash flow | report ↗ |
| 2025-Q2 | — | $25M | $165M | $26M-$33M operating cash flow | report ↗ |
| 2025-Q1 | — | $29M | $118M+ <$0.1M short-term inv. | $52M-$39M operating cash flow | report ↗ |
| 2024-Q3 | — | $25M | $113M+ <$0.1M short-term inv. | $24M-$24M operating cash flow | report ↗ |
| 2024-Q2 | $10M | $18M | $84M+ <$0.1M short-term inv. | $8.3M-$28M operating cash flow | report ↗ |
| 2024-Q1 | — | $18M | $83M+ $29M short-term inv. | $34M-$28M operating cash flow | report ↗ |
| 2023-Q3 | — | $14M | $97M+ $71M short-term inv. | $20M-$17M operating cash flow | report ↗ |
| 2023-Q2 | — | $13M | $184M+ <$0.1M short-term inv. | $24M-$20M operating cash flow | report ↗ |
| 2023-Q1 | — | $12M | $99M+ $14M short-term inv. | $16M-$20M operating cash flow | report ↗ |
| 2022-Q3 | — | $11M | $79M+ $26M short-term inv. | $18M-$15M operating cash flow | report ↗ |
| 2022-Q2 | — | $15M | $64M+ $30M short-term inv. | $22M-$13M operating cash flow | report ↗ |
| 2022-Q1 | $2.6M | $14M | $47M+ $60M short-term inv. | $17M-$19M operating cash flow | report ↗ |
| 2021-Q3 | $0 | $9.3M | $25M+ $79M short-term inv. | $23M-$11M operating cash flow | report ↗ |
Annual history (5 years)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2025-FY | $31M | $115M | $205M | $210M | report ↗ |
Verastem reported full-year 2025 revenue of $30.9M, with prior-year revenue not disclosed. R&D spend was $114.6M, up 41.0% YoY from $81.3M, while cash and equivalents stood at $205M as of December 31, 2025. Quarterly net burn was reported at $209.5M, and no net income or loss figure was disclosed.
The company guided to a cash runway into the first half of 2027 and said the LGSOC commercial launch and development program should become self-sustaining by the second half of 2026. Clinical priorities include an interim update on the VS-7375 Phase 1/2 trial in 1H 2026, a topline readout from the fully enrolled RAMP 301 Phase 3 trial in mid-2027, and a RAMP 205 expansion update in Q2 2026. Updated RAMP 201J data showed a confirmed ORR of 38% overall, including 57% in KRAS-mutated LGSOC patients. The company also noted the exercise of outstanding cash warrants, netting $29.4M.
View 4 more years
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2024-FY | $10M | $81M | $89M | $33M-$105M operating cash flow | report ↗ |
| 2023-FY | — | $61M | $79M+ $59M short-term inv. | $22M-$86M operating cash flow | report ↗ |
| 2022-FY | $2.6M | $51M | $76M+ $13M short-term inv. | $18M-$64M operating cash flow | report ↗ |
| 2021-FY | $2.0M | $39M | $21M+ $79M short-term inv. | $18M-$54M operating cash flow | report ↗ |
Insider transactions
Open-market activity, trailing 12 months: 0 purchases ($0), 32 sales ($1.1M). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.
| Source | ||||||
|---|---|---|---|---|---|---|
| 2026-11-03 | Paterson Dan · director, President and CEO | Open-market sale | 1,299 | $9.60 | $12K | Form 4 |
| 2026-10-01 | Calkins Daniel · Chief Financial Officer | Open-market sale | 2,566 | $8.00 | $21K | Form 4 |
| 2026-10-01 | Paterson Dan · director, President and CEO | Open-market sale | 44,121 | $8.00 | $353K | Form 4 |
| 2026-09-30 | Calkins Daniel · Chief Financial Officer | Award / grant | 8,333 | — | — | Form 4 |
| 2026-09-30 | Paterson Dan · director, President and CEO | Award / grant | 106,893 | — | — | Form 4 |
| 2026-09-21 | Calkins Daniel · Chief Financial Officer | Open-market sale | 55 | $7.70 | $424 | Form 4 |
| 2026-08-03 | Paterson Dan · director, President and CEO | Open-market sale | 1,302 | $5.81 | $8K | Form 4 |
| 2026-06-22 | Calkins Daniel · Chief Financial Officer | Open-market sale | 4,032 | $4.18 | $17K | Form 4 |
Institutional holders
From SEC Form 13F filings for the quarter ended 2026-03-31 (filed up to 45 days later). 155 reporting institutions held 81.4M shares ($428.4M, 64.6% of shares outstanding).
| # | Institution | Shares | Value |
|---|---|---|---|
| 1 | RTW INVESTMENTS, LP | 6,576,306 | $34.9M |
| 2 | BlackRock, Inc. | 6,194,925 | $32.8M |
| 3 | Deep Track Capital, LP | 5,740,850 | $30.4M |
| 4 | ARMISTICE CAPITAL, LLC | 4,592,000 | $24.3M |
| 5 | Nantahala Capital Management, LLC | 3,584,820 | $19.0M |
| 6 | STATE STREET CORP | 3,516,651 | $18.6M |
| 7 | VANGUARD CAPITAL MANAGEMENT LLC | 3,322,770 | $17.6M |
| 8 | Stonepine Capital Management, LLC | 3,302,300 | $17.5M |
| 9 | Foresite Capital Management VI LLC | 3,146,631 | $16.7M |
| 10 | MILLENNIUM MANAGEMENT LLC | 2,411,965 | $12.8M |
| 11 | CITADEL ADVISORS LLC | 2,308,669 | $12.2M |
| 12 | MORGAN STANLEY | 2,247,273 | $11.9M |
| 13 | Rosalind Advisors, Inc. | 2,138,475 | $11.3M |
| 14 | Alyeska Investment Group, L.P. | 2,050,000 | $10.9M |
| 15 | AIGH Capital Management LLC | 2,000,000 | $10.6M |